Isonicotinic Acid Hydrazide (INH) Pretreatment With Misoprostol Versus Misoprostol Alone in Missed Abortion
- Sponsor
- Aswan University Hospital
- Study ID
- NCT04500002
- Status
- Unknown
Conditions
- IUCD Complication
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - 45 Years
- Healthy Volunteers
- Not accepted
Interventions
- Isonicotinic Acid Hydrazide — DRUGtotal dose 900 mg per day for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion
- Misoprostol — DRUGMisoprosrol 800mcg will be given to all patients for induction of abortion
Study Details
The primary endpoint was the success rate of adjuvant isonicotinic acid hydrazide (INH) and misoprostol versus misoprostol alone for medical termination of first-trimester pregnancy.
Key Dates
- Start date
- Sep 1, 2020
- Status verified
- Aug 2020
- Primary completion
- Jun 30, 2021
- Completion
- Jul 30, 2021
Study Design
- Enrollment
- 240 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- PREVENTION
Arms
- Experimental: INH3 tablets of isonicotinic acid hydrazide 300 mg will be given as single daily doses, 5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum three doses.
- Active Comparator: MisoprostolMisoprostol Alone 800 mcg every three hours up to maximum three doses
Primary Outcome Measure
number of patients with complete abortion [ Time Frame: 12 hours ]
Central Contacts
- hany f Sallam, md+20102435461
- nahla waer Shady+201022336052